Literature DB >> 32324723

Notes from the Field: Outbreak of Human Immunodeficiency Virus Infection Among Persons Who Inject Drugs - Cabell County, West Virginia, 2018-2019.

Amy Atkins, R Paul McClung, Michael Kilkenny, Kyle Bernstein, Kara Willenburg, Anita Edwards, Sheryl Lyss, Erica Thomasson, Nivedha Panneer, Nathan Kirk, Meg Watson, Elizabeth Adkins, Elizabeth DiNenno, Vicki Hogan, Robyn Neblett Fanfair, Kathleen Napier, Alison D Ridpath, Michelle Perdue, Mi Chen, Tamara Surtees, Senad Handanagic, Heather Wood, Daphne Kennebrew, Caitlin Cohn, Samira Sami, Scott Eubank, Nathan W Furukawa, Bridget Rose, Antoine Thompson, Lauren Spadafora, Carolyn Wright, Shawn Balleydier, Dawn Broussard, Pam Reynolds, Neal Carnes, Nils Haynes, Tobey Sapiano, Shannon McBee, Ellsworth Campbell, Samantha Batdorf, Melissa Scott, Miracle Boltz, David Wills, Alexandra M Oster.   

Abstract

Entities:  

Year:  2020        PMID: 32324723      PMCID: PMC7188413          DOI: 10.15585/mmwr.mm6916a2

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


× No keyword cloud information.
In January 2019, West Virginia Bureau for Public Health (WVBPH) surveillance staff members noted an increase in diagnoses of human immunodeficiency virus (HIV) infection among persons who inject drugs in Cabell County, West Virginia (population approximately 91,900*). Cabell County, part of a medium-sized metropolitan statistical area and home to the city of Huntington (population approximately 46,000†), had historically high rates of substance use disorder but low rates of HIV infection (). During 2013–2017, an annual average of two diagnoses of HIV infection had occurred among Cabell County persons who inject drugs; however, in 2018, 14 diagnoses occurred, including seven in the fourth quarter. WVBPH requested assistance from CDC for a public health investigation and response. WVBPH, the Cabell-Huntington Health Department (CHHD), and CDC investigated to characterize the outbreak and guide public health interventions. Initial investigation found that at the time this increase in diagnoses of HIV infection was detected, access to HIV testing and preexposure prophylaxis (PrEP) in Cabell County was limited. Although a harm reduction program, including access to sterile syringes, had been operating at CHHD since September 2015, stricter requirements, including proof of Cabell County residency, were initiated in May 2018, which limited access to these services. Moreover, knowledge about HIV, the outbreak, and treatment for substance use disorder was low, and initiation of treatment for HIV or substance use disorder among persons who inject drugs was also low. Interventions to address these challenges were rapidly scaled up by staff members from WVBPH, CHHD, CDC, and community partners. A case was defined as a new diagnosis of HIV infection during January 1, 2018–October 9, 2019 in 1) a person who injects drugs (regardless of other risk factors), who resided or was homeless in Cabell County at diagnosis, whose HIV diagnosis occurred in Cabell County, or who reported injecting drugs or accessing syringe services in Cabell County; or 2) a sex or needle-sharing partner of someone meeting criterion 1; or 3) a person whose HIV-1 polymerase sequence was linked at a genetic distance of ≤0.5% to that of a person meeting criterion 1 (). CDC staff members provided surge capacity to interview persons with a new diagnosis of HIV and offer HIV prevention services to approximately 600 identified partners and social contacts of these persons. Screening events were conducted to test persons at high risk, provide health education, and link or reengage persons in HIV care. The team worked with local hospitals, clinics, substance use disorder treatment providers, and community-based organizations to scale up HIV testing at locations where persons who inject drugs accessed services. A social network strategy driven by peer recruitment was implemented to reach persons who inject drugs who were not already engaged in the harm reduction program and their sexual and social contacts. The team also partnered with local infectious disease providers and support staff members to improve linkage to HIV and hepatitis C virus care and reengagement for persons who were no longer in care. Interviews were conducted with persons who inject drugs who also reported exchanging sex for money or drugs to identify barriers (e.g., stigma, discrimination, and location and hours of services) that might hinder access to prevention services and to guide service delivery. In addition, the team expanded access to PrEP by training new providers and supporting PrEP implementation at CHHD and two community health systems. As of January 26, 2020, a total of 82 persons had met the case definition (Table). Among 61 (74%) persons with a CD4+ count measured ≤3 months after diagnosis, median CD4+ count was 583 (range = 6–1,057), indicating that many infections were recent. Among 50 persons who had an available HIV-1 polymerase sequence test result, 46 (92%) were part of a single cluster of closely related infections, indicating rapid transmission. As a result of the combined response activities, approximately 450 new clients enrolled in the harm reduction program, including approximately 50 persons living with HIV infection. CDC assisted in the development of educational campaigns and materials related to HIV infection, substance use disorder, stigma, PrEP, safe injection, and safe syringe and needle disposal for persons who inject drugs and community members. WVBPH and CHHD continue to work together in this response, and WVBPH is improving preparedness for detecting and responding to other clusters and outbreaks statewide through enhanced surveillance.
TABLE

Characteristics of persons with outbreak-associated human immunodeficiency virus infection — Cabell County, West Virginia, January 1, 2018–October 9, 2019*

CharacteristicNo. (%)
Total
82 (100)
Sex
Male
49 (60)
Female
33 (40)
Age group (yrs)
<20
0 (0)
20–39
61 (74)
≥40
21 (26)
Race/Ethnicity
White, non-Hispanic
75 (92)
Black, non-Hispanic
1 (1)
Hispanic
1 (1)
Other
5 (6)
Transmission category
Injection drug use
75 (92)
Male-to-male sex and injection drug use
6 (7)
Male-to-male sex
1 (1)
Exchanged sex for money or drugs
24 (29)
Laboratory evidence of current or past hepatitis C virus infection 72 (88)

* Data were last updated on January 26, 2020.

* Data were last updated on January 26, 2020.
  2 in total

1.  Estimating the Number of People Who Inject Drugs in A Rural County in Appalachia.

Authors:  Sean T Allen; Allison O'Rourke; Rebecca Hamilton White; Kristin E Schneider; Michael Kilkenny; Susan G Sherman
Journal:  Am J Public Health       Date:  2019-01-24       Impact factor: 9.308

2.  Identifying Clusters of Recent and Rapid HIV Transmission Through Analysis of Molecular Surveillance Data.

Authors:  Alexandra M Oster; Anne Marie France; Nivedha Panneer; M Cheryl Bañez Ocfemia; Ellsworth Campbell; Sharoda Dasgupta; William M Switzer; Joel O Wertheim; Angela L Hernandez
Journal:  J Acquir Immune Defic Syndr       Date:  2018-12-15       Impact factor: 3.731

  2 in total
  13 in total

1.  Substance Use Disorder Treatment Providers' Knowledge and Opinions Toward Testing and Treatment of Chronic Hepatitis C in Rural North Carolina.

Authors:  Donna M Evon; Christopher B Hurt; Delesha M Carpenter; Sarah K Rhea; Caitlin M Hennessy; William A Zule
Journal:  Rural Ment Health       Date:  2022-02-03

2.  Testing a digitally distributed method to recruit a network of community organizations to fight the consequences of the drug epidemic: A study in 13 American states.

Authors:  Haesung Jung; Aashna Sunderrajan; Marta Durantini; Edgardo Sanchez; Liliane Windsor; Man-Pui Sally Chan; Thomas O'Brien; Bita Fayaz Farkhad; Alex Karan; Carol A Lee; Soonhyung Kwon; Dolores Albarracín
Journal:  J Community Psychol       Date:  2022-03-28

3.  Surveillance for endemic infectious disease outbreaks: Adaptive sampling using profile likelihood estimation.

Authors:  Michael Fairley; Isabelle J Rao; Margaret L Brandeau; Gary L Qian; Gregg S Gonsalves
Journal:  Stat Med       Date:  2022-05-08       Impact factor: 2.497

4.  Expansion of Preexposure Prophylaxis Capacity in Response to an HIV Outbreak Among People Who Inject Drugs-Cabell County, West Virginia, 2019.

Authors:  Nathan W Furukawa; Mathew Weimer; Kara S Willenburg; Michael E Kilkenny; Amy D Atkins; R Paul McClung; Zachary Hansen; Kathleen Napier; Senad Handanagic; Neal A Carnes; Jeffrey Kemp Rinderle; Robyn Neblett-Fanfair; Alexandra M Oster; Dawn K Smith
Journal:  Public Health Rep       Date:  2021-03-01       Impact factor: 2.792

5.  HIV detection by an emergency department HIV screening program during a regional outbreak among people who inject drugs.

Authors:  Kiran A Faryar; Rachel M Ancona; Zachary Reau; Sheryl B Lyss; Robert S Braun; Todd Rademaker; Ryane K Sickles; Michael S Lyons
Journal:  PLoS One       Date:  2021-05-18       Impact factor: 3.240

6.  The CDC HIV Outbreak Coordination Unit: Developing a Standardized, Collaborative Approach to HIV Outbreak Assessment and Response.

Authors:  Alexandra M Oster; Anne Marie France; Robert P McClung; Kate Buchacz; Sheryl B Lyss; Philip J Peters; Paul J Weidle; William M Switzer; Stanley A Phillip; John T Brooks; Angela L Hernandez
Journal:  Public Health Rep       Date:  2021-05-28       Impact factor: 3.117

Review 7.  Drugs of Abuse and Their Impact on Viral Pathogenesis.

Authors:  Jason T Blackard; Kenneth E Sherman
Journal:  Viruses       Date:  2021-11-29       Impact factor: 5.048

8.  Factors Associated with Likelihood of Initiating Others into Injection Drug Use Among People Who Inject Drugs in West Virginia.

Authors:  Sean T Allen; Kristin E Schneider; Alyona Mazhnaya; Rebecca Hamilton White; Allison O'Rourke; Alex H Kral; Ricky N Bluthenthal; Michael E Kilkenny; Susan G Sherman
Journal:  AIDS Behav       Date:  2021-06-02

9.  Awareness of and interest in oral pre-exposure prophylaxis (PrEP) for HIV prevention and interest in hypothetical forms of PrEP among people who inject drugs in rural West Virginia.

Authors:  Kristin E Schneider; Rebecca Hamilton White; Allison O'Rourke; Michael E Kilkenny; Michelle Perdue; Susan G Sherman; Suzanne M Grieb; Sean T Allen
Journal:  AIDS Care       Date:  2020-09-21

10.  Impact of medications for opioid use disorder among persons hospitalized for drug use-associated skin and soft tissue infections.

Authors:  Joshua A Barocas; Mam Jarra Gai; Brenda Amuchi; Raagini Jawa; Benjamin P Linas
Journal:  Drug Alcohol Depend       Date:  2020-08-01       Impact factor: 4.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.